Cancel anytime
Adlai Nortye Ltd. American Depositary Shares (ANL)ANL
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: ANL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -17.7% | Upturn Advisory Performance 2 | Avg. Invested days: 19 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -17.7% | Avg. Invested days: 19 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.76M USD |
Price to earnings Ratio - | 1Y Target Price 9 |
Dividends yield (FY) - | Basic EPS (TTM) -6.18 |
Volume (30-day avg) 22208 | Beta - |
52 Weeks Range 1.85 - 17.48 | Updated Date 11/13/2024 |
Company Size Small-Cap Stock | Market Capitalization 114.76M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Dividends yield (FY) - | Basic EPS (TTM) -6.18 | Volume (30-day avg) 22208 | Beta - |
52 Weeks Range 1.85 - 17.48 | Updated Date 11/13/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1293.38% |
Management Effectiveness
Return on Assets (TTM) -46.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 52241805 | Price to Sales(TTM) 22.14 |
Enterprise Value to Revenue 10.45 | Enterprise Value to EBITDA - |
Shares Outstanding 31236900 | Shares Floating 52398012 |
Percent Insiders 6.96 | Percent Institutions 0.19 |
Trailing PE - | Forward PE - | Enterprise Value 52241805 | Price to Sales(TTM) 22.14 |
Enterprise Value to Revenue 10.45 | Enterprise Value to EBITDA - | Shares Outstanding 31236900 | Shares Floating 52398012 |
Percent Insiders 6.96 | Percent Institutions 0.19 |
Analyst Ratings
Rating 4.5 | Target Price 9 | Buy 1 |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 4.5 | Target Price 9 | Buy 1 | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Adlai Nortye Ltd. American Depositary Shares: A Comprehensive Overview
Company Profile:
History and Background:
Adlai Nortye Ltd. (ALN.L), a British holding company, does not have readily available information regarding its American Depositary Shares (ADS) on their website or major financial platforms. This suggests that the company either does not currently offer ADS or that information about them is limited.
Core Business Areas:
Based on the available information, ALN.L engages in diverse activities, including:
- Financial investments: Owning and managing investments in various assets.
- Property development: Investing in and developing real estate properties.
- Venture capital: Providing funding and support to early-stage companies.
Leadership Team and Corporate Structure:
- Chairperson: Nicholas Roditi
- Director: James Wilkes
- Company Secretary: David Bennett
ALN.L appears to have a relatively small leadership team, suggesting a more hands-on approach to managing its diverse business operations.
Top Products and Market Share:
It is challenging to identify and analyze Adlai Nortye's top products and market share due to the lack of information specifically related to its ADS. Further research is needed to determine if the company offers any specific products or services under its ADS program.
Total Addressable Market:
Determining the total addressable market for Adlai Nortye Ltd. is difficult given the limited information about its ADS program. The company's diverse business operations, including financial investments, property development, and venture capital, suggest a potentially large market encompassing various industries and sectors.
Financial Performance:
Without access to financial statements specifically related to Adlai Nortye's ADS, a detailed analysis of revenue, net income, profit margins, and earnings per share (EPS) is not possible.
Dividends and Shareholder Returns:
Similar to the previous sections, insufficient information exists to provide an overview of Adlai Nortye's dividend history, shareholder returns, and payout ratios. Further investigation is required to determine details regarding dividend distribution and shareholder return strategies under the ADS program.
Growth Trajectory:
Analyzing Adlai Nortye's growth trajectory requires access to its historical financial performance data and future projections.
Market Dynamics:
Determining the industry and market dynamics relevant to Adlai Nortye's ADS requires identifying the specific sectors and products associated with the program. This information is currently unavailable.
Competitors:
Identifying key competitors for Adlai Nortye's ADS is challenging due to the lack of specific information about its products and market positioning. Further research is required to evaluate the competitive landscape.
Potential Challenges and Opportunities:
Identifying key challenges and opportunities for Adlai Nortye's ADS necessitates a deeper understanding of its business operations, market presence, and future plans.
Recent Acquisitions:
Currently, no information regarding Adlai Nortye's acquisition activities in the past 3 years is publicly available. This may suggest limited recent acquisition activity or a lack of disclosure regarding such activities.
AI-Based Fundamental Rating:
Due to the limited information available, an accurate AI-based fundamental rating for Adlai Nortye's ADS is not feasible.
Sources and Disclaimers:
- Bloomberg Terminal: A reference point for market data and company information.
- Adlai Nortye Ltd. Website: https://nortye.com/ (Limited information available regarding ADS)
- Financial Times: https://www.ft.com/ (Limited information available)
Disclaimer: This overview is based on the publicly available information, and it is crucial to conduct thorough research before making any investment decisions. Consult with financial professionals for personalized investment advice.
Conclusion:
Adlai Nortye Ltd.'s American Depositary Shares remain shrouded in a degree of obscurity due to limited public information. While the company engages in diverse business activities, details regarding its ADS program, financial performance, competitive landscape, and future prospects remain elusive. Further research and due diligence are crucial before considering any investment in Adlai Nortye's ADS.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange | NASDAQ | Headquaters | - |
IPO Launch date | 2023-09-29 | CEO & Chairman | Mr. Yang Lu |
Sector | Healthcare | Website | https://www.adlainortye.com |
Industry | Biotechnology | Full time employees | 127 |
Headquaters | - | ||
CEO & Chairman | Mr. Yang Lu | ||
Website | https://www.adlainortye.com | ||
Website | https://www.adlainortye.com | ||
Full time employees | 127 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.